American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy

Brachytherapy. 2021 Nov-Dec;20(6):1200-1218. doi: 10.1016/j.brachy.2021.05.011. Epub 2021 Jul 21.


Purpose: Growing data supports the role of radiation therapy in the treatment of soft tissue sarcoma (STS). Brachytherapy has been used for decades in the management of STS and can be utilized as monotherapy or as a boost to external beam radiation. We present updated guidelines from the American Brachytherapy Society regarding the utilization of brachytherapy in the management of STS.

Methods and materials: Members of the American Brachytherapy Society with expertise in STS and STS brachytherapy created an updated clinical practice guideline including step-by-step details for performing STS brachytherapy based on a literature review and clinical experience.

Results: Brachytherapy monotherapy should be considered for lower-recurrence risk patients or after a local recurrence following previous external beam radiation; a brachytherapy boost can be considered in higher-risk patents meeting implant criteria. Multiple dose/fractionation regimens are available, with determination based on tumor location and treatment intent. Techniques to limit wound complications are based on the type of wound closure; wound complication can be mitigated with a delay in the start of brachytherapy with immediate wound closure or by utilizing a staged reconstruction technique, which allows an earlier treatment start with a delayed wound closure.

Conclusions: These updated guidelines provide clinicians with data on indications for STS brachytherapy as well as guidelines on how to perform and deliver high quality STS brachytherapy safely with minimal toxicity.

Keywords: Brachytherapy; Radiation; Soft tissue sarcoma.

MeSH terms

  • Brachytherapy* / methods
  • Consensus
  • Dose Fractionation, Radiation
  • Humans
  • Sarcoma* / radiotherapy
  • Soft Tissue Neoplasms*
  • United States